Rheumatoid arthritis is an autoimmune disease, specifically classified as an immune-mediated inflammatory disease. Unlike osteoarthritis, which results from physical wear on joints, rheumatoid arthritis occurs when the immune system mistakenly attacks the body’s own joint tissue. It affects roughly 18 million people worldwide, with women two to three times more likely to develop it than men.
How the Immune System Attacks the Joints
In a healthy immune system, white blood cells identify and destroy foreign invaders like bacteria and viruses. In rheumatoid arthritis, this system misfires. Immune cells target the synovium, the thin membrane lining every joint capsule. The synovium normally produces a small amount of fluid that lubricates the joint and nourishes the cartilage. When the immune system attacks it, the membrane becomes inflamed, thickens, and begins producing excess fluid that causes swelling and pain.
The chain of events starts with specific immune cells. T cells become activated and in turn activate B cells, which produce antibodies directed against the body’s own proteins. Macrophages, a type of immune cell that acts as a first responder, flood the synovial lining and release a cascade of inflammatory chemicals. These chemicals are what drive the actual tissue damage: they erode cartilage, weaken bone, and stretch the tendons and ligaments that hold the joint together.
One of the most distinctive features of RA involves a process called citrullination. Certain enzymes in the body modify proteins in the joints, and the immune system develops antibodies against these modified proteins. These antibodies, detectable through a blood test called anti-CCP, are over 98% specific for rheumatoid arthritis, making them one of the most reliable markers for distinguishing RA from other joint conditions.
More Than a Joint Disease
Because rheumatoid arthritis is a systemic autoimmune condition, the inflammation isn’t confined to the joints. About 40% of people with RA develop problems in other parts of the body, including the skin, eyes, lungs, heart, kidneys, blood vessels, and nervous system. This is a key distinction from osteoarthritis, which only affects individual joints and the structures immediately around them. The widespread inflammation in RA can contribute to cardiovascular risk, lung scarring, and dry eyes, among other complications.
What Causes the Immune System to Misfire
No single cause triggers rheumatoid arthritis. Instead, a combination of genetic susceptibility and environmental factors sets the stage. The strongest genetic link involves a specific region of immune system genes. A particular genetic marker called the shared epitope appears in approximately 70% of people who develop the antibody-positive form of RA. Carrying two copies of this marker raises the risk further. But genetics alone don’t determine who gets the disease.
Smoking is the most well-established environmental trigger. It appears to promote the protein modifications (citrullination) that the immune system reacts against, particularly in people who carry the genetic risk factors. Interestingly, a species of oral bacteria associated with gum disease, Porphyromonas gingivalis, also has the ability to trigger citrullination, which has led researchers to investigate a link between periodontal disease and the earliest stages of RA development.
How RA Differs From Osteoarthritis
People often confuse rheumatoid arthritis with osteoarthritis because both cause joint pain. But the underlying disease type is completely different. Osteoarthritis is a degenerative condition caused by cartilage breaking down over time, typically worsening with age and joint use. Rheumatoid arthritis is driven by immune system dysfunction and can strike at any age.
The pattern of symptoms also differs. RA typically affects joints symmetrically: if the knuckles on your left hand are swollen, the same knuckles on your right hand likely are too. It favors smaller joints first, especially in the hands and feet. Osteoarthritis tends to affect weight-bearing joints like knees and hips, often unevenly. Morning stiffness is another telling sign. In osteoarthritis, stiffness after waking typically fades within 30 minutes. In RA, morning stiffness commonly lasts well beyond that, sometimes for hours, and is accompanied by fatigue that feels disproportionate to your activity level.
How RA Is Diagnosed
There’s no single test that confirms rheumatoid arthritis. Doctors use a scoring system developed jointly by the American College of Rheumatology and the European League Against Rheumatism. It evaluates four areas: how many and which joints are involved, whether blood tests show specific antibodies, whether markers of inflammation are elevated, and how long symptoms have lasted. A score of 6 out of 10 or higher, combined with confirmed joint swelling that can’t be explained by another condition, leads to a diagnosis.
Two blood tests play a central role. Rheumatoid factor (RF) is the older test, with sensitivity ranging from 55% to 90%, meaning it misses some cases. The anti-CCP antibody test is more precise, with about 68% sensitivity but over 95% specificity, so a positive result strongly points to RA. Doctors also measure inflammation levels through blood tests that track how quickly red blood cells settle in a tube (ESR) and levels of a protein the liver produces during inflammation (CRP). During a severe flare, ESR values of 50 to 80 are common.
How the Disease Progresses
Rheumatoid arthritis moves through four recognized stages if left poorly controlled. The first stage, synovitis, involves inflammation of the joint lining with swelling and pain but no permanent damage yet. In the second stage, the inflamed tissue forms a thick, abnormal layer called pannus that begins to invade cartilage and bone. The third stage brings fibrous ankylosis, where scar tissue forms between the bones of the joint and restricts movement. The final stage, bony ankylosis, occurs when the bones actually fuse together and the joint becomes immobile.
This progression is not inevitable. Modern treatment strategies aim to catch the disease early and suppress immune activity aggressively before structural damage occurs.
What Remission Looks Like Today
The goal of RA treatment has shifted dramatically over the past two decades. Rather than simply managing pain, the current approach targets remission or the lowest possible disease activity. Medications that modify the immune response are started early and adjusted frequently based on objective measures of inflammation and joint damage.
Real-world data shows this strategy works. In one cohort followed for 10 years under closely monitored treatment, 68% of patients achieved clinical remission and 73% had minimal structural joint damage. When disease activity was well controlled throughout that period, over 90% maintained both structural and functional health. By contrast, patients whose disease was poorly controlled saw remission rates drop to around 11 to 17%. The gap between those outcomes underscores why early diagnosis and consistent treatment matter so much in a disease that, by its nature, is progressive.